Subcutaneous heparin treatment increases survival in small cell lung cancer

1994277 citationsJournal Articlebronze Open Access

Authors

B Lebeau

Claude Chastang · Département d'Informatique

J.-M. Bréchot · Hôtel-Dieu de Paris

Frédérique Capron · Hôtel-Dieu de Paris

Bertrand Dautzenberg · Sorbonne Université

C Delaisements · Hôpital Ambroise-Paré

M. Mornet · Centre Hospitalier de l'Agglomération de Nevers

Abstract

These results confirm the value of anticoagulant treatment in SCLC, already suspected for warfarin and now proven for heparin, but the modes of administration and the biologic explanations for this activity still warrant further investigation.

Topics & Keywords

Lung Cancer Research Studies Neuroendocrine Tumor Research Advances Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 74, Issue 1, pp. 38-45

DOI: 10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e

Field-Weighted Citation Impact: 0.73